Similar articles

• Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.

  Harker LA, Hanson SR, Kelly AB. Harker LA, et al. Thromb Haemost. 1995 Jul;74(1):464-72. Thromb Haemost. 1995. PMID: 8578508 Review. No abstract available.
• Leeches to hirulogs and other thrombin-directed antithrombotics.

  Fenton JW 2nd. Fenton JW 2nd. Hematol Oncol Clin North Am. 1992 Oct;6(5):1121-9. Hematol Oncol Clin North Am. 1992. PMID: 1400076 Review.
• Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.

  Komatsu Y, Inoue Y, Goto Y, Fukazawa T, Hayashi H. Komatsu Y, et al. Thromb Haemost. 1999 Feb;81(2):250-5. Thromb Haemost. 1999. PMID: 10064001
• Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance.

  Verstraete M. Verstraete M. Thromb Haemost. 1997 Jul;78(1):357-63. Thromb Haemost. 1997. PMID: 9198179 Review. No abstract available.
• Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.

  Biemond BJ, Friederich PW, Levi M, Vlasuk GP, Büller HR, ten Cate JW. Biemond BJ, et al. Circulation. 1996 Jan 1;93(1):153-60. doi: 10.1161/01.cir.93.1.153. Circulation. 1996. PMID: 8616922